T cells expressing chemokine receptors for treating cancer
AssigneeThe University of Adelaide
InventorShaun Reuss Mccoll
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and products for preventing and/or treating cancer, and in particular to methods, cells and products for preventing and/or treating cancer using adoptive immunotherapies. In certain embodiments, the present disclosure provides a method of treating a subject suffering from, or susceptible to, a cancer associated with chemokine expressing cells, the method comprising exposing the subject to T cells expressing a receptor to the chemokine and thereby treating the subject.
Claims19
1-25. (canceled)
A method of treating a central nervous system (CNS) disorder or disease in a subject, the method comprising administering, to the subject, lymphocytes engineered to express a chemokine receptor, wherein the chemokine receptor is CCR2 and/or CCR6.
Dependencies are inferred from the claim text.